Blastic plasmacytoid dendritic cell neoplasms: Clinico-immunohistochemical correlations in a series of 91 patients

American Journal of Surgical Pathology

Volumn 38, Issue 5, 2014, Pages 673-680

  Julia, Fanny ^a   Dalle, Stephane ^a   Duru, Gerard ^b   Balme, Brigitte ^b   Vergier, Béatrice ^c   Ortonne, Nicolas ^d   Vignon Pennamen, Marie D ^e   Costes Martineau, Valérie ^g   Lamant, Laurence ^h   Dalac, Sophie ^e   Delattre, Claire ^k   Déchelotte, Pierre ^l   Courville, Philippe ^m   Carlotti, Agnès ^e   De Muret, Anne ⁿ   Fraitag, Sylvie ^f   Levy, Annie ^o   Mitchell, Andrew ^p   Petrella, Tony ^i,j  

^a Departments of Dermatology   (France)

^b UNIVERSITÉ LYON 1   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e Department of Pathology Hô Pital Henri Mondor APHP ^*  (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g MONTPELLIER UNIVERSITY HOSPITAL   (France)

^h CHU PURPAN   (France)

ⁱ DIJON UNIVERSITY HOSPITAL   (France)

^j Centre de Pathologie   (France)

^k LILLE UNIVERSITY HOSPITAL   (France)

^l UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^m HÔPITAL CHARLES NICOLLE   (France)

ⁿ UNIVERSITY HOSPITAL OF TOURS   (France)

^o ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^p MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

more..

Author keywords

BPDCN; CD303; immunohistochemistry; Ki 67; prognostic factor

Indexed keywords

TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DENDRITIC CELL; FEMALE; HEMATOLOGIC DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; SKIN TUMOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DENDRITIC CELLS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84899112043     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000156     Document Type: Article

References (24)

1. Facchetti F, Jones D, Petrella T. Blastic plasmacytoid dendritic cellneoplasm. In: Tumors WHOCo, ed. WHO Classification of Tumorsof Haematopoietic and Lymphoid Tissues. Lyon, France: IARCPress; 2008:145-147.
2. Jegalian AG, Facchetti F, Jaffe ES. Plasmacytoid dendritic cells:physiologic roles and pathologic states. Adv Anat Pathol. 2009;16:392-404.
3. Garnache-Ottou F, Feuillard J, Saas P. Plasmacytoid dendritic cellleukaemia/lymphoma: towards a well defined entity Br J Haematol.2007;136: 539-548. (Pubitemid 46148191)
4. Cota C, Vale E, Viana I, et al. Cutaneous manifestations of blasticplasmacytoid dendritic cell neoplasm-morphologic and phenotypicvariability in a series of 33 patients. Am J Surg Pathol. 2010;34:75-87.
5. Marafioti T, Paterson JC, Ballabio E, et al. Novel markers ofnormal and neoplastic human plasmacytoid dendritic cells. Blood.2008;111:3778-3792.
6. Petrella T, Facchetti F. Tumoral aspects of plasmacytoid dendriticcells: what do we know in 2009 Autoimmunity. 2010;43:210-214.
7. Dalle S, Beylot-Barry M, Bagot M, et al. Blastic plasmacytoiddendritic cell neoplasm: is transplantation the treatment of choiceBr J Dermatol. 2010;162:74-79.
8. Lucioni M, Novara F, Fiandrino G, et al. Twenty-one cases ofblastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus9p21.3 deletion. Blood. 2011;118:4591-4594.
9. Jaye DL, Geigerman CM, Herling M, et al. Expression of theplasmacytoid dendritic cell marker BDCA-2 supports a spectrum ofmaturation among CD4+ CD56+ hematodermic neoplasms. ModPathol. 2006;19:1555-1562. (Pubitemid 44789923)
10. Hashikawa K, Niino D, Yasumoto S, et al. Clinicopathologicalfeatures and prognostic significance of CXCL12 in blastic plasmacytoiddendritic cell neoplasm. J Am Acad Dermatol. 2012;66:278-291.
11. Petrella T, Herve G, Bonnotte B, et al. Alpha-interferon secretingblastic plasmacytoid dendritic cells neoplasm: a case report withhistological, molecular genetics and long-term tumor cells culturestudies. Am J Dermatopathol. 2012;34:626-631.
12. Julia F, Petrella T, Beylot-Barry M, et al. Blastic plasmacytoiddentritic cell neoplasm: clinical features in 90 patients. Br JDermatol. 2013;169:579-586.
13. Jaffe ES, Ralfkiaer E. Mature T-cell and NK-cell neoplasms. In:Tumors WHOCo, ed. Pathology and Genetics of Tumors ofHaematopoietic and Lymphoid Tissues. Lyon, France: IARC Press;2001:191-235.
14. Petrella T, Dalac S, Maynadie M, et al. CD4+ CD56+ cutaneousneoplasms: a distinct hematological entity Groupe Francaisd'Etude des Lymphomes Cutanes (GFELC). Am J Surg Pathol.1999;23:137-146.
15. Rollins-Raval M, Pillai R, Warita K, et al. CD123 immunohistochemicalexpression in acute myeloid leukemia is associated withunderlying FLT3-ITD and NPM1 mutations. Appl ImmunohistochemMol Morphol. 2013;21:212-217.
16. Garnache-Ottou F, Feuillard J, Ferrand C, et al. Extendeddiagnostic criteria for plasmacytoid dendritic cell leukaemia. Br JHaematol. 2009;145:624-636.
17. Ascani S, Massone C, Ferrara G, et al. CD4-negative variant ofCD4+/CD56+ hematodermic neoplasm: description of three cases.J Cutan Pathol. 2008;35:911-915.
18. Bekkenk MW, Jansen PM, Meijer CJ, et al. CD56+ hematologicalneoplasms presenting in the skin: a retrospective analysis of 23 newcases and 130 cases from the literature. Ann Oncol. 2004;15:1097-1108. (Pubitemid 39089788)
19. Momoi A, Toba K, Kawai K, et al. Cutaneous lymphoblasticlymphoma of putative plasmacytoid dendritic cell-precursor origin:two cases. Leuk Res. 2002;26:693-698. (Pubitemid 34465707)
20. Petrella T, Bagot M, Willemze R, et al. Blastic NK-cell lymphomas(agranular CD4+CD56+ hematodermic neoplasms): a review. Am JClin Pathol. 2005;123:662-675. (Pubitemid 40586484)
21. Niakosari F, Sur M. Agranular CD4+/CD56+ hematodermicneoplasm: a distinct entity described in the recent World HealthOrganization-European Organization for Research and Treatmentof Cancer classification for cutaneous lymphomas. Arch Pathol LabMed. 2007;131:149-151. (Pubitemid 46174152)
22. Jegalian AG, Buxbaum NP, Facchetti F, et al. Blastic plasmacytoiddendritic cell neoplasm in children: diagnostic features and clinicalimplications. Haematologica. 2010;95:1873-1879.
23. Jahn PS, Zanker KS, Schmitz J, et al. BDCA-2 signaling inhibitsTLR-9-agonist-induced plasmacytoid dendritic cell activation andantigen presentation. Cell Immunol. 2010;265:15-22.
24. Dzionek A, Sohma Y, Nagafune J, et al. BDCA-2, a novelplasmacytoid dendritic cell-specific type II C-type lectin, mediatesantigen capture and is a potent inhibitor of interferon alpha/betainduction. J Exp Med. 2001;194:1823-1834. (Pubitemid 34028661)